Autolus Therapeutics plc (AUTL)

3.8000 -0.2000 (-5.00%) At close: 04:00PM EDT

Autolus Therapeutics plc

The Mediaworks
191 Wood Lane White City
London W12 7FP
United Kingdom
44 20 3829 6230
https://www.autolus.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 463

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christian Martin Itin Ph.D.	CEO & Director	2.4M	N/A	1964
Dr. Martin Pule M.D., MBBS	Founder, Senior VP & Chief Scientific Officer	N/A	N/A	1972
Mr. Robert F. Dolski	Senior VP & CFO	N/A	N/A	1971
Mr. Christopher Vann	Senior VP & COO	N/A	N/A	1965
Mr. David Brochu	Senior VP & Chief Technical Officer	N/A	N/A	1956
Mr. Alexander Swan	Senior VP & Chief Human Resources Officer	N/A	N/A	1965
Mr. Brent Rice	Senior VP, Chief Commercial Officer & Site Head of US	N/A	N/A	1966
Ms. Olivia Manser	Director of Investor Relations	N/A	N/A	N/A
Mr. Alex Driggs	Senior VP of Legal Affairs & General Counsel and Secretary	N/A	N/A	N/A
Dr. Chris Williams	Senior VP & Chief Business Development Officer	N/A	N/A	1980

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Corporate governance

Autolus Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.